All In Biotech

Drug Trial Radar · NCT07324837

Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of the Recombinant Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset (FRIDA-CT)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,050 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,050

Planned (sponsor's estimate)

Start

Jun 9, 2026

Primary completion

Nov 1, 2028

Study completion Jan 1, 2029

Sponsor

Lead sponsor
Supergene, LLCIndustry
Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

Conditions

  • Ischemic Stroke, Acute

Interventions

  • non-immunogenic staphylokinaseDrug

    The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

  • PlaceboDrug

    Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Excellent functional outcomeTime frame: 90 days

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Chelyabinsk Regional Clinical Hospital No. 3

    Chelyabinsk, Russia · Recruiting

  • Irkutsk Regional Clinical Hospital

    Irkutsk, Russia · Recruiting

  • Interregional Clinical and Diagnostic Center

    Kazan', Russia · Recruiting

  • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1

    Krasnodar, Russia · Recruiting

  • Krasnogorsk Clinical Hospital

    Krasnogorsk, Russia · Recruiting

  • Moscow Multidisciplinary Clinical Center "Kommunarka"

    Moscow, Russia · Recruiting

  • N.I. Pirogov Russian National Research Medical University

    Moscow, Russia · Recruiting

  • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital

    Nizhny Novgorod, Russia · Not yet recruiting

  • V.I. Voynov Orenburg Regional Clinical Hospital

    Orenburg, Russia · Recruiting

  • St. Petersburg Hospital for War Veterans

    Saint Petersburg, Russia · Recruiting

  • Leningradskaya Regional Clinical Hospital

    Saint Petersburg, Russia · Recruiting

  • Solnechnogorsk District Hospital

    Solnechnogorsk, Russia · Not yet recruiting

  • Tver Regional Clinical Hospital

    Tver', Russia · Recruiting

  • Ulyanovsk Regional Clinical Hospital

    Ulyanovsk, Russia · Recruiting

  • City Clinical Hospital of Emergency Medical Care No. 25

    Volgograd, Russia · Recruiting

  • Sverdlovsk Regional Clinical Hospital No. 1

    Yekaterinburg, Russia · Recruiting

  • Ryazan Regional Clinical Hospital

    Ryazan, Ryazan Oblast, Russia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.